资讯

Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study
BAYRY subsidiary Vividion Therapeutics doses the first patient in a phase I study on VVD-159642 to treat advanced solid ...
Medical Dialogues5 天
Bayer AG arm Vividion Therapeutics doses first patient in Phase I study of Inhibitor for ...
Vividion Therapeutics, Inc. has announced that the first patient has been dosed in a Phase I clinical trial evaluating ...
Vividion begins subject dosing in trial of RAS-driven cancer treatment
The therapy is the fourth clinical-stage programme derived from the company’s chemoproteomics discovery platform.
PipelineReview.com5 天
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for ...
SAN DIEGO, CA, USA & BERLIN, Germany I April 03, 2025 I Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a ...
Tourmaline Bio: We Should Wait For Upcoming Phase 2b Trial Data
Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.
Vividion Therapeutics, Inc.: Vividion Therapeutics Doses First Patient in Phase I Study of ...
VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Ka, a key signaling pathway ...